Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Eli Lilly | NYSE | Healthcare | Pharmaceuticals | $825.47B | 39x | 0.42 | $888.89 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.6% Upside | Upgrade to Pro+ | |
| J&J | NYSE | Healthcare | Pharmaceuticals | $572.36B | 27.2x | -7.06 | $237.14 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 4.5% Upside | Upgrade to Pro+ | |
| AbbVie | NYSE | Healthcare | Pharmaceuticals | $364.29B | 87.2x | -70.78 | $205.87 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.4% Upside | Upgrade to Pro+ | |
| Roche Holding ADR | OTC Markets | Healthcare | Pharmaceuticals | $335.94B | 19.8x | 0.36 | $50.87 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.8% Upside | Upgrade to Pro+ | |
| AstraZeneca | NYSE | Healthcare | Pharmaceuticals | $312.32B | 30.6x | 0.68 | $199.57 | -2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 8.1% Upside | Upgrade to Pro+ | |
| Merck&Co | NYSE | Healthcare | Pharmaceuticals | $296.29B | 16.1x | 2.02 | $117.42 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13% Upside | Upgrade to Pro+ | |
| Novartis ADR | NYSE | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $150.90 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.2% Downside | Upgrade to Pro+ | |
| Novartis | OTC Markets | Healthcare | Pharmaceuticals | $290.24B | 21.3x | 0.96 | $146.25 | -6.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Amgen | NASDAQ | Healthcare | Pharmaceuticals | $186.61B | 24.1x | 0.28 | $345.40 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 0% Upside | Upgrade to Pro+ | |
| Novo Nordisk ADR | NYSE | Healthcare | Pharmaceuticals | $176.58B | 11x | 6.03 | $39.95 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.5% Upside | Upgrade to Pro+ | |
| Gilead | NASDAQ | Healthcare | Pharmaceuticals | $172.15B | 20.3x | 0.01 | $138.65 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.7% Upside | Upgrade to Pro+ | |
| Pfizer | NYSE | Healthcare | Pharmaceuticals | $153.93B | 19.8x | -5.94 | $27.03 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 1% Upside | Upgrade to Pro+ | |
| Bristol-Myers Squibb | NYSE | Healthcare | Pharmaceuticals | $117.13B | 16.5x | 0.09 | $57.24 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9.7% Upside | Upgrade to Pro+ | |
| GSK plc | OTC Markets | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $29.24 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| GSK plc DRC | NYSE | Healthcare | Pharmaceuticals | $115.96B | 15.2x | 0.12 | $57.57 | -2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -5.4% Downside | Upgrade to Pro+ | |
| Sanofi ADR | NASDAQ | Healthcare | Pharmaceuticals | $115.93B | 20.2x | 0.45 | $47.74 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.6% Upside | Upgrade to Pro+ | |
| Vertex | NASDAQ | Healthcare | Pharmaceuticals | $113.01B | 28.7x | 0.03 | $439.15 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.6% Upside | Upgrade to Pro+ | |
| McKesson | NYSE | Healthcare | Pharmaceuticals | $105.66B | 24.8x | 0.41 | $862.04 | -0.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.9% Upside | Upgrade to Pro+ | |
| Chugai Pharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $89.67B | 32.8x | 2.67 | $27.21 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Regeneron Pharma | NASDAQ | Healthcare | Pharmaceuticals | $76.21B | 17.9x | 2.1 | $740.13 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.1% Upside | Upgrade to Pro+ | |
| Merck ADR | OTC Markets | Healthcare | Pharmaceuticals | $60.15B | 19.5x | -3.18 | $27.60 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.7% Upside | Upgrade to Pro+ | |
| UCB ADR | OTC Markets | Healthcare | Pharmaceuticals | $59.87B | 32.5x | 0.71 | $156.97 | -1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 7.9% Upside | Upgrade to Pro+ | |
| Takeda Pharma ADR | NYSE | Healthcare | Pharmaceuticals | $56.15B | 80.2x | -1.71 | $17.85 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
| Takeda Pharma | OTC Markets | Healthcare | Pharmaceuticals | $56.15B | 80.2x | -1.73 | $34.52 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Zoetis Inc | NYSE | Healthcare | Pharmaceuticals | $50.79B | 20.1x | 1.89 | $120.72 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.7% Upside | Upgrade to Pro+ | |
| Cardinal Health | NYSE | Healthcare | Pharmaceuticals | $49.95B | 30.5x | 1.04 | $212.30 | -1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
| CSL | OTC Markets | Healthcare | Pharmaceuticals | $47.79B | 34.9x | -0.68 | $25.42 | 2.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29% Upside | Upgrade to Pro+ | |
| Bayer AG PK | OTC Markets | Healthcare | Pharmaceuticals | $47.28B | -11.1x | 0.26 | $11.96 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.4% Upside | Upgrade to Pro+ | |
| Alnylam | NASDAQ | Healthcare | Pharmaceuticals | $44.07B | 142.6x | 0.69 | $332.58 | -2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 32.7% Upside | Upgrade to Pro+ | |
| HALEON ADR | NYSE | Healthcare | Pharmaceuticals | $43.19B | 19.7x | 1.07 | $9.65 | -0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.2% Upside | Upgrade to Pro+ | |
| Teva ADR | NYSE | Healthcare | Pharmaceuticals | $36.70B | 25.9x | 0.14 | $31.34 | -1.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.9% Upside | Upgrade to Pro+ | |
| Sandoz | OTC Markets | Healthcare | Pharmaceuticals | $36.53B | 39.5x | $84.97 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
| Otsuka ADR | OTC Markets | Healthcare | Pharmaceuticals | $35.05B | 15.4x | 1.89 | $33.35 | 0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.8% Upside | Upgrade to Pro+ | |
| Daiichi Sankyo ADR | OTC Markets | Healthcare | Pharmaceuticals | $32.48B | 17.2x | 0.61 | $18.55 | 6.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 46.2% Upside | Upgrade to Pro+ | |
| Astellas Pharma Inc | OTC Markets | Healthcare | Pharmaceuticals | $29.24B | 14.5x | 0.02 | $16.40 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.6% Upside | Upgrade to Pro+ | |
| Royalty Pharma | NASDAQ | Healthcare | Pharmaceuticals | $27.90B | 27.1x | -3.97 | $48.36 | -0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5.4% Upside | Upgrade to Pro+ | |
| Biogen | NASDAQ | Healthcare | Pharmaceuticals | $26.18B | 20.2x | -0.95 | $177.70 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.7% Upside | Upgrade to Pro+ | |
| United Therapeutics | NASDAQ | Healthcare | Pharmaceuticals | $25.48B | 19.3x | 1.45 | $581.22 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.1% Upside | Upgrade to Pro+ | |
| Moderna | NASDAQ | Healthcare | Pharmaceuticals | $21.33B | -7.4x | -0.34 | $53.89 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -23.5% Downside | Upgrade to Pro+ | |
| Roivant Sciences | NASDAQ | Healthcare | Pharmaceuticals | $20.73B | -24.7x | 0.04 | $28.99 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.3% Upside | Upgrade to Pro+ | |
| Incyte | NASDAQ | Healthcare | Pharmaceuticals | $19.40B | 15.2x | 0 | $97.43 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 9% Upside | Upgrade to Pro+ | |
| Shionogi ADR | OTC Markets | Healthcare | Pharmaceuticals | $17.80B | 14.4x | 0.93 | $10.35 | -1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.9% Upside | Upgrade to Pro+ | |
| Viatris | NASDAQ | Healthcare | Pharmaceuticals | $16.12B | -4.6x | 0.01 | $13.82 | -0.7% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 21.6% Upside | Upgrade to Pro+ | |
| Ipsen ADR | OTC Markets | Healthcare | Pharmaceuticals | $15.90B | 30.9x | 1.08 | $49.15 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Swedish Orphan Biovitrum AB ADR | OTC Markets | Healthcare | Pharmaceuticals | $15.57B | 300.6x | -1.8 | $20.87 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| BridgeBio Pharma | NASDAQ | Healthcare | Pharmaceuticals | $14.90B | -20.3x | 0.66 | $76.91 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25.8% Upside | Upgrade to Pro+ | |
| Sino Biopharma ADR | OTC Markets | Healthcare | Pharmaceuticals | $14.07B | 41x | -1.23 | $15.89 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| CSPC Pharmaceutical Group | OTC Markets | Healthcare | Pharmaceuticals | $13.83B | 24.1x | -2.97 | $1.02 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
| Neurocrine | NASDAQ | Healthcare | Pharmaceuticals | $13.13B | 28.2x | 0.65 | $131.54 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 41.4% Upside | Upgrade to Pro+ | |
| Pharming | NASDAQ | Healthcare | Pharmaceuticals | $12.93B | 4,577.5x | 3.63 | $18.31 | 3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ |